Quest Diagnostics Management

Management criteria checks 3/4

Quest Diagnostics' CEO is Jim Davis, appointed in Nov 2022, has a tenure of 1.42 years. total yearly compensation is $12.67M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.067% of the company’s shares, worth $10.14M. The average tenure of the management team and the board of directors is 5.1 years and 7.5 years respectively.

Key information

Jim Davis

Chief executive officer

US$12.7m

Total compensation

CEO salary percentage	9.3%
CEO tenure	1.4yrs
CEO ownership	0.07%
Management average tenure	5.1yrs
Board average tenure	7.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jim Davis's remuneration changed compared to Quest Diagnostics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	US$842m
Dec 31 2023	US$13m	US$1m	US$850m
Sep 30 2023	n/a	n/a	US$759m
Jun 30 2023	n/a	n/a	US$790m
Mar 31 2023	n/a	n/a	US$789m
Dec 31 2022	US$12m	US$806k	US$942m
Sep 30 2022	n/a	n/a	US$1b
Jun 30 2022	n/a	n/a	US$1b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	US$4m	US$625k	US$2b
Sep 30 2021	n/a	n/a	US$2b
Jun 30 2021	n/a	n/a	US$2b
Mar 31 2021	n/a	n/a	US$2b
Dec 31 2020	US$4m	US$577k	US$1b
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	US$749m
Mar 31 2020	n/a	n/a	US$771m
Dec 31 2019	US$3m	US$590k	US$835m
Sep 30 2019	n/a	n/a	US$709m
Jun 30 2019	n/a	n/a	US$707m
Mar 31 2019	n/a	n/a	US$720m
Dec 31 2018	US$3m	US$590k	US$733m
Sep 30 2018	n/a	n/a	US$860m
Jun 30 2018	n/a	n/a	US$808m
Mar 31 2018	n/a	n/a	US$782m
Dec 31 2017	US$3m	US$590k	US$769m

Compensation vs Market: Jim's total compensation ($USD12.67M) is above average for companies of similar size in the UK market ($USD5.63M).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.

CEO

Jim Davis (60 yo)

1.4yrs

Tenure

US$12,673,834

Compensation

Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
James Davis	Chairman	1.4yrs	US$12.67m	0.067% $ 10.1m
Sam Samad	Executive VP & CFO	1.8yrs	US$3.98m	0.0037% $ 556.6k
Michael Prevoznik	Senior VP & General Counsel	24.7yrs	US$2.25m	0.035% $ 5.2m
Catherine Doherty	Executive Vice President of Regional Businesses	no data	US$3.16m	0.058% $ 8.8m
Karthik Kuppusamy	Senior Vice President of Clinical Solutions	1.7yrs	US$2.02m	0.0086% $ 1.3m
Michael Deppe	Senior VP	5yrs	no data	0.032% $ 4.8m
Gabrielle Wolfson	Senior VP and Chief Information & Digital Officer	5.2yrs	no data	no data
Shawn Bevec	Vice President of Investor Relations	no data	no data	no data
Kristin Wallace	Senior VP & Chief Compliance Officer	1.5yrs	no data	no data
Gary Samuels	Senior VP & Chief Communications Officer	27.4yrs	no data	no data
Cecilia McKenney	Senior VP & Chief Human Resources Officer	6.2yrs	no data	no data
Dermot Shorten	Senior Vice President of Strategy	8.2yrs	no data	no data

5.1yrs

Average Tenure

60yo

Average Age

Experienced Management: 0KSX's management team is seasoned and experienced (5.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
James Davis	Chairman	1.4yrs	US$12.67m	0.067% $ 10.1m
Timothy Main	Independent Director	10.3yrs	US$315.44k	0.019% $ 2.8m
Timothy Ring	Lead Independent Director	12.3yrs	US$345.94k	no data
Gary Pfeiffer	Independent Director	19.3yrs	US$342.12k	no data
Gail Wilensky	Independent Director	27.3yrs	US$304.82k	0.028% $ 4.2m
Denise Morrison	Independent Director	5.2yrs	US$312.33k	0.0026% $ 388.1k
Vicky Gregg	Independent Director	9.8yrs	US$314.44k	0.012% $ 1.8m
Wright Lassiter	Independent Director	4.1yrs	US$300.44k	no data
Tracey Doi	Independent Director	2.7yrs	US$300.44k	no data
Luiz Diaz	Independent Director	less than a year	no data	no data

7.5yrs

Average Tenure

65.5yo

Average Age

Experienced Board: 0KSX's board of directors are considered experienced (7.5 years average tenure).

Quest Diagnostics Management

Management criteria checks 3/4

Key information

Recent management updates

Quest Diagnostics Incorporated, Annual General Meeting, May 16, 2024

Quest Diagnostics, Inc. Appoints Yuri A. Fesko, M.D. as Senior Vice President and Chief Medical Officer

Quest Diagnostics Elects Luis A. Diaz to Its Board

Quest Diagnostics Announces Jim Davis Joins Board of Directors

Quest Diagnostics Incorporated Announces Executive Changes

Quest Diagnostics Incorporated Announces Management Changes

Recent updates

First quarter 2024 earnings released: EPS: US$1.75 (vs US$1.80 in 1Q 2023)

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated, Annual General Meeting, May 16, 2024

Upcoming dividend of US$0.75 per share

Quest Diagnostics Incorporated to Report Q1, 2024 Results on Apr 23, 2024

Full year 2023 earnings released: EPS: US$7.59 (vs US$8.12 in FY 2022)

Quest Diagnostics Incorporated Announces the Launch of MelaNodal Predict

Quest Diagnostics Incorporated Announces the Availability of the First Consumer-Initiated, Physician-Ordered Blood-Draw Test for PFAS Chemicals

Dividend of US$0.75 announced

Full year 2023 earnings released: EPS: US$7.63 (vs US$8.12 in FY 2022)

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated to Report Q4, 2023 Results on Feb 01, 2024

Upcoming dividend of US$0.71 per share at 2.0% yield

Quest Diagnostics, Inc. Appoints Yuri A. Fesko, M.D. as Senior Vice President and Chief Medical Officer

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 31, 2024

Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States

Third quarter 2023 earnings released: EPS: US$1.99 (vs US$2.19 in 3Q 2022)

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year 2023

Quest Diagnostics Incorporated to Report Q3, 2023 Results on Oct 24, 2023

Upcoming dividend of US$0.71 per share at 2.3% yield

Quest Diagnostics Grants Fda Breakthrough Designation for Its Adeno-Associated Virus Test

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on October 23, 2023

QuQuest Diagnostics Introduces First-To-Market Consumer-Initiated Blood Test for Alzheimer's Disease Risk Assessment on questhealth.com

Quest Diagnostics Incorporated Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$2.09 (vs US$1.99 in 2Q 2022)

Quest Diagnostics Announces the Launch of its First Consumer-Initiated Genetic Test

Upcoming dividend of US$0.71 per share at 2.0% yield

Quest Diagnostics Incorporated to Report Q2, 2023 Results on Jul 26, 2023

Quest Diagnostics Elects Luis A. Diaz to Its Board

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 25, 2023

First quarter 2023 earnings released: EPS: US$1.80 (vs US$2.98 in 1Q 2022)

Now 20% undervalued

Upcoming dividend of US$0.71 per share at 2.1% yield

Quest Diagnostics Incorporated (NYSE:DGX) entered into a definitive agreement to acquire Select Assets of the Laboratory Services Business from The New York and Presbyterian Hospital.

Now 20% undervalued after recent price drop

Full year 2022 earnings released: EPS: US$8.12 (vs US$15.90 in FY 2021)

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2023

Quest Diagnostics Incorporated to Report Q4, 2022 Results on Feb 02, 2023

Upcoming dividend of US$0.66 per share

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select assets of Summa Health System, Inc.

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on February 1, 2023

Quest Diagnostics Announces Jim Davis Joins Board of Directors

Third quarter 2022 earnings released: EPS: US$2.19 (vs US$4.09 in 3Q 2021)

Quest Diagnostics Incorporated Announces Executive Changes

Quest Diagnostics Incorporated Announces Management Changes

Quest Diagnostics Incorporated (NYSE:DGX) entered into a definitive agreement to acquire Select assets of Summa Health System, Inc.

Quest Diagnostics Incorporated to Report Q3, 2022 Results on Oct 20, 2022

Upcoming dividend of US$0.66 per share

FDA Authorizes Quest Diagnostics' Proprietary Monkeypox Test for Emergency Use

Quest Diagnostics Aims to Close Gaps in Maternal Healthcare with New Obstetrics Test Panel That Includes Hepatitis C Screening

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on October 19, 2022

Second quarter 2022 earnings released: EPS: US$1.99 (vs US$5.02 in 2Q 2021)

Quest Diagnostics Incorporated Revises Consolidated Earnings Guidance for the Full Year of 2022

Quest Diagnostics Launches Monkeypox Virus Testing

Upcoming dividend of US$0.66 per share

Quest Diagnostics Incorporated to Report Q2, 2022 Results on Jul 21, 2022

New Quest Diagnostics Health Trends Study, in Collaboration with Cdc, Shows Less Than Half of Pregnant People Screened for Hepatitis C

Quest Diagnostics Incorporated Names Sam Samad as Executive Vice President with Effect from July 11, 2022

Quest Diagnostics Incorporated Announces the resignation of Carrie Eglinton Manner as Senior Vice President, Advanced and General Diagnostics and Clinical Solutions

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on July 20, 2022

First quarter 2022 earnings released: EPS: US$2.98 (vs US$3.52 in 1Q 2021)

First quarter 2022 earnings released: EPS: US$2.98 (vs US$3.52 in 1Q 2021)

Quest Diagnostics Incorporated Provides Consolidated Earnings Guidance for the Fiscal Year 2022

Quest Diagnostics Incorporated Announces Mark Guinan Will Retire as Chief Financial Officer

Quest Diagnostics Incorporated to Report Q1, 2022 Results on Apr 21, 2022

Upcoming dividend of US$0.66 per share

Quest Diagnostics Incorporated, Annual General Meeting, May 18, 2022

Senior VP & General Counsel recently sold US$86k worth of stock